Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02424279

Enrollment

Registered

2015-04-23

Start date

2014-09-30

Completion date

2017-09-30

Last updated

2015-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Pancreatic Cancer

Keywords

pancreatic cancer, pain, splanchnicectomy

Brief summary

Pancreatic cancer is a difficult to treat disease, mainly due to the fact that diagnosis is made usually in the late stage of this condition. One of the treatment methods of pain accompanying this neoplasm is thoracoscopic splanchnicectomy. It has been shown that it is a safe procedure with a small percentage of complications, nevertheless it is often use as the last stage in pain management what significantly decreases its effectiveness. The aim of this study is to determinate the effect of invasive pain treatment (splanchnicectomy) in patients with advanced pancreatic cancer on subjective pain perception at rest, in movement and after meals (measured with the BPI, QLQ- C30 and FACIT questionnaires), and suffering (measured with PRISM projection test), the use of painkillers during the disease and patients' overall survival. Moreover the investigators want to check if early performance of splanchnicectomy (on lower steps of analgesic ladder WHO) is combined with better therapeutic effect of this treatment.

Interventions

PROCEDURESplanchnicectomy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients diagnosed with pancreatic cancer * Age over 18 years * Signed informed consent to participate in the study

Exclusion criteria

* Age under 18 years * Intellectual inability to fill the questionnaires * Co-occurrence of a disease in which significant chronic pain exists, which was recognized before the onset of pancreatic cancer

Design outcomes

Primary

Measure	Time frame
Change from baseline pain intensity at 1 year (BPI questionnaires)	one year

Secondary

Measure	Time frame
Quality of life and pain intensity measurement (measured with the QLQ- C30, FACIT and BPI questionnaires)	From date of randomization until the date of death from any cause,assessed up to 100 months

Countries

Poland

Contacts

Primary ContactŁukasz Dobosz, M.D.

lukaszdobosz@gumed.edu.pl0048583493010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026